These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 38791279)

  • 1. Effect of Immunosuppression on the Immune Response to SARS-CoV-2 Infection and Vaccination.
    Leacy EJ; Teh JW; O'Rourke AM; Brady G; Gargan S; Conlon N; Scott J; Dunne J; Phelan T; Griffin MD; Power J; Mooney A; Naughton A; Kiersey R; Gardiner M; O'Brien C; Mullan R; Flood R; Clarkson M; Townsend L; O'Shaughnessy M; Dyer AH; Moran B; Fletcher JM; Zgaga L; Little MA;
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response.
    Filippini F; Giacomelli M; Bazzani C; Fredi M; Semeraro P; Tomasi C; Franceschini F; Caruso A; Cavazzana I; Giagulli C
    BMC Med; 2023 Jun; 21(1):210. PubMed ID: 37316832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.
    Prendecki M; Clarke C; Edwards H; McIntyre S; Mortimer P; Gleeson S; Martin P; Thomson T; Randell P; Shah A; Singanayagam A; Lightstone L; Cox A; Kelleher P; Willicombe M; McAdoo SP
    Ann Rheum Dis; 2021 Oct; 80(10):1322-1329. PubMed ID: 34362747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Immunity Over 2 Years Following Vaccination and Infection.
    Juhl AK; Dietz LL; Søgaard OS; Reekie J; Nielsen H; Johansen IS; Benfield T; Wiese L; Stærke NB; Jensen TØ; Olesen R; Iversen K; Fogh K; Bodilsen J; Madsen LW; Lindvig SO; Raben D; Andersen SD; Hvidt AK; Andreasen SR; Baerends EAM; Lundgren J; Østergaard L; Tolstrup M;
    J Infect Dis; 2024 Sep; 230(3):e605-e615. PubMed ID: 38687181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
    Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
    Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients.
    Konuma T; Hamatani-Asakura M; Nagai E; Adachi E; Kato S; Isobe M; Monna-Oiwa M; Takahashi S; Yotsuyanagi H; Nannya Y
    Int J Hematol; 2024 Aug; 120(2):229-240. PubMed ID: 38842630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
    Harrington P; Doores KJ; Radia D; O'Reilly A; Lam HPJ; Seow J; Graham C; Lechmere T; McLornan D; Dillon R; Shanmugharaj Y; Espehana A; Woodley C; Saunders J; Curto-Garcia N; O'Sullivan J; Raj K; Kordasti S; Malim MH; Harrison C; de Lavallade H
    Br J Haematol; 2021 Sep; 194(6):999-1006. PubMed ID: 34085278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of T-cell and Humoral Immune Response to SARS-CoV-2 Antigens in Rituximab-Treated Patients with Rheumatoid Arthritis Vaccinated with Combined Vector Vaccine Gam-COVID-Vac.
    Omelchenko VO; Kurochkina YD; Fedorova AV; Ovchinnikov VS; Koval VV; Bratko IV; Letyagina EA; Korolev MA
    Bull Exp Biol Med; 2024 Apr; 176(6):786-790. PubMed ID: 38896315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
    Ewer KJ; Barrett JR; Belij-Rammerstorfer S; Sharpe H; Makinson R; Morter R; Flaxman A; Wright D; Bellamy D; Bittaye M; Dold C; Provine NM; Aboagye J; Fowler J; Silk SE; Alderson J; Aley PK; Angus B; Berrie E; Bibi S; Cicconi P; Clutterbuck EA; Chelysheva I; Folegatti PM; Fuskova M; Green CM; Jenkin D; Kerridge S; Lawrie A; Minassian AM; Moore M; Mujadidi Y; Plested E; Poulton I; Ramasamy MN; Robinson H; Song R; Snape MD; Tarrant R; Voysey M; Watson MEE; Douglas AD; Hill AVS; Gilbert SC; Pollard AJ; Lambe T;
    Nat Med; 2021 Feb; 27(2):270-278. PubMed ID: 33335323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
    Schramm R; Costard-Jäckle A; Rivinius R; Fischer B; Müller B; Boeken U; Haneya A; Provaznik Z; Knabbe C; Gummert J
    Clin Res Cardiol; 2021 Aug; 110(8):1142-1149. PubMed ID: 34241676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
    Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
    Front Immunol; 2022; 13():834981. PubMed ID: 35154159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
    Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
    EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies.
    Amodio D; Ruggiero A; Sgrulletti M; Pighi C; Cotugno N; Medri C; Morrocchi E; Colagrossi L; Russo C; Zaffina S; Di Matteo G; Cifaldi C; Di Cesare S; Rivalta B; Pacillo L; Santilli V; Giancotta C; Manno EC; Ciofi Degli Atti M; Raponi M; Rossi P; Finocchi A; Cancrini C; Perno CF; Moschese V; Palma P
    Front Immunol; 2021; 12():727850. PubMed ID: 34671350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
    Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Chen Y; Claußnitzer A; Haibel H; Proft F; Guerra G; Durek P; Heinrich F; Ferreira-Gomes M; Burmester GR; Radbruch A; Mashreghi MF; Lino AC; Dörner T
    Arthritis Rheumatol; 2022 Jun; 74(6):934-947. PubMed ID: 34962360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
    de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE
    Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
    Apostolidis SA; Kakara M; Painter MM; Goel RR; Mathew D; Lenzi K; Rezk A; Patterson KR; Espinoza DA; Kadri JC; Markowitz DM; E Markowitz C; Mexhitaj I; Jacobs D; Babb A; Betts MR; Prak ETL; Weiskopf D; Grifoni A; Lundgreen KA; Gouma S; Sette A; Bates P; Hensley SE; Greenplate AR; Wherry EJ; Li R; Bar-Or A
    Nat Med; 2021 Nov; 27(11):1990-2001. PubMed ID: 34522051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination.
    Riise J; Meyer S; Blaas I; Chopra A; Tran TT; Delic-Sarac M; Hestdalen ML; Brodin E; Rustad EH; Dai KZ; Vaage JT; Nissen-Meyer LSH; Sund F; Wader KF; Bjornevik AT; Meyer PA; Nygaard GO; König M; Smeland S; Lund-Johansen F; Olweus J; Kolstad A
    Br J Haematol; 2022 Jun; 197(6):697-708. PubMed ID: 35254660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
    Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Doevelaar A; Hölzer B; Paniskaki K; Dolff S; Wilde B; Witzke O; Braun J; Stervbo U; Babel N
    Ann Rheum Dis; 2021 Oct; 80(10):e162. PubMed ID: 34272253
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.